Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
Biotech
Processa hands cancer drug back to Opus over time, cost involved
The portfolio streamlining is meant to help Processa focus on another oncology asset, a modified precursor of approved chemotherapy 5-fluorouracil.
Darren Incorvaia
Jul 1, 2025 11:12am
‘New realm of biology’: missing Y chromosomes worsen cancer
Jun 6, 2025 1:12pm
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
May 29, 2025 7:30pm
BioNTech makes £1B commitment to expand UK research, build HQ
May 20, 2025 11:15am
Drug shrinks tumors in mice by targeting extrachromosomal DNA
Nov 6, 2024 12:50pm
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
